Naurex reveals promising data with oral depression candidate
This article was originally published in Scrip
Naurex has presented positive Phase II data with the second depression candidate in its pipeline, NRX-1074, an oral NMDA receptor partial agonist. This follows Phase IIb data reported recently with Naurex's lead program, GLYX-13, which also targets the NMDA receptor (scripintelligence.com, 11 December 2014).
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.